Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Google Secures Pentagon AI Deal for Classified Projects 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
EAST RUTHERFORD, N.J., Feb. 05, 2016 -- Cambrex Corporation (NYSE:CBM) announced that fourth quarter 2015 financial results will be released on Tuesday, February 9, 2016 before the market opens.
The Company will host a conference call to discuss the financial results.
Fourth Quarter 2015 Earnings Conference Call
When: Tuesday, February 9, 2016 at 8:30 a.m. Eastern Time
Dial-in: 1-800-905-0392 for U.S.
1-785-830-1913 for International
Passcode: 2549872
Dial-in Replay: 1-888-203-1112 for U.S.
1-719-457-0820 for International
Passcode: 2549872
Available through Tuesday, February 16, 2016
Webcast: www.cambrex.com
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura Investor Relations Associate Phone: 201.804.3037 Email: [email protected]
